SecBot SecBot
8-K ·Filed Aug 4, 2026

RYTM

RHYTHM PHARMACEUTICALS, INC.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001628280-26-052170
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q2 beat and accelerating U.S. launch trajectory for IMCIVREE in acquired HO validate the commercial thesis. The positive RM-718 data de-risks the pipeline and supports a potential next-generation weekly option. Watch for the Japanese PMDA decision on setmelanotide for acquired HO (expected H2 2026) and European launches (2027) as the next major catalysts. The narrowed OpEx guidance suggests improved operating discipline.

DirectionBullish
Confidencehigh
Horizonweeks

IMCIVREE

▲ Bullish Named in this 8-K
Impact
Not rated
Phase
Not stated
Time to market
Not stated
Next catalyst
None dated

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, next catalyst and thesis.

Subscribe for Full Access

Price Chart

Loading chart...

Executive Summary

Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M (vs $67.7M consensus, +5.3% beat) and a GAAP EPS loss of -$0.73 (vs -$0.83 consensus, a 12.0% beat), driven by a strong U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO). The company also announced positive preliminary Phase 2 data for its weekly injectable MC4R agonist RM-718, showing an -11.6% mean BMI reduction at 16 weeks, and narrowed its 2026 Non-GAAP OpEx guidance to $363M-$397M (from $385M-$415M). The combination of a top- and bottom-line beat, accelerating U.S. revenue growth (+38% QoQ), and encouraging pipeline data is a clear positive signal for the commercial story and long-term growth trajectory.

Key Financial Metrics

EPS
−$0.73
est −$0.83 · +12.1%
Revenue
$71.3M
est $67.7M · +5.3% · +47.0% YoY
Rating
beat
Gross Margin
87.47%

Key Facts

  • Q2 2026 net product revenue of $71.3M, up 19% sequentially from Q1 2026 and 47% YoY.
  • U.S. revenue of $51.0M (72% of total), up 38% sequentially, driven by acquired HO launch demand.
  • GAAP EPS loss of -$0.73 beat consensus of -$0.83 by 12.0%.
  • More than 400 patient start forms for IMCIVREE in acquired HO received from ~300 prescribers since FDA approval on March 19, 2026.
  • Preliminary Phase 2 data for RM-718 showed -11.6% mean BMI reduction at 16 weeks (n=7), comparable to setmelanotide and bivamelagon.
  • 2026 Non-GAAP OpEx guidance narrowed to $363M-$397M (from $385M-$415M), with R&D guidance lowered to $175M-$195M.
  • Cash, cash equivalents, and short-term investments of $330.9M as of June 30, 2026, expected to fund operations for at least 24 months.

Financial Impact

Revenue beat consensus by $3.6M (+5.3%); EPS beat by $0.10 (+12.0%)

revenueepscash positionoperating expenses

Risk Factors

  • Ex-U.S. revenue declined 13% sequentially due to a $3.8M retrospective charge in France, indicating potential pricing/reimbursement headwinds in international markets.
  • The company remains pre-profitable with a net loss of -$50.4M in Q2 2026, though cash runway extends at least 24 months.
  • RM-718 data is preliminary (n=7 at 16 weeks); larger and longer-term data are needed to confirm durability and safety profile.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-052170
Document: 0001628280-26-052170-index-headers.html0001628280-26-052170
Document: 0001628280-26-052170-index.html0001628280-26-052170
Document: 0001628280-26-052170.txt0001628280-26-052170
8-K Data (Synthetic)0001628280-26-052170

Track record

26 reports on RYTM

Performance horizon

9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (11h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026